SCHEMBL31685784

SCHEMBL31685784

CC(=O)OC[C@H]1O[C@@H](n2ccc(=O)nc2N(C)C)[C@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.52
▸ THRB P10828 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ HIF1A Q16665 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ TP53 P04637 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ PRKCA P17252 1/20 0.46
▸ AKT1 P31749 1/20 0.46
▸ PTK2 Q05397 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ GALR3 O60755 1/20 0.45
▸ CA1 P00915 10/20 0.44
▸ CA2 P00918 10/20 0.44
▸ CA12 O43570 9/20 0.44
▸ CA9 Q16790 8/20 0.44
▸ CA14 Q9ULX7 7/20 0.44
▸ PRKAB2 O43741 1/20 0.43
▸ PRKAG1 P54619 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31685331 0.86 LMNA (0.54) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL31685440 0.84 LMNA (0.51) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL31685354 0.83 LMNA (0.54) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL31685325 0.82 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
Uridine Triacetate SCHEMBL15780051 0.81 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
Uridine Triacetate SCHEMBL15779809 0.81 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL2238447 0.80 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL10813233 0.80 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL9068649 0.80 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL6536598 0.80 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE TEAM MEDICAL, LLC 2025-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE SYNCRIP, SNRPA, RNASE1 LMNA 240/4885THRB 4546/4885SMN1; SMN2 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback